Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, P...
Raised $83.6 million in gross proceeds from common stock offering STOPS™ and CAM programs: initial data presented at conferences, dosing in 2 nd CHB cohorts ongoing Clinical trial application filed for 3 rd CHB drug candidate ALG-0202572 ...
SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the co...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Gainers: Alterity Therapeutics Limited (ATHE) +68%.TRxADE HEALTH (MEDS) +57%.Marin Software (MRIN) +45%.Bridgeline Digital (BLIN) +35%.Birks (BGI) +25%.Pulse Biosciences (PLSE) +25%.SGOCO Group (SGOC) +22%.Grid Dynamics Holdings (GDYN) +19%.scPharmaceuticals (SCPH) +18%.U.S. Silica Holdi...
SOUTH SAN FRANCISCO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of $19.00 per share. In addition, Aligos has granted the und...
Gainers: BSQUARE Corporation (BSQR) +99%.Cerevel Therapeutics Holdings (CERE) +94%.Marin Software Incorporated (MRIN) +73%.Exela Technologies (XELA) +43%.Weidai (WEI) +39%.Infobird (IFBD) +36%.Powerbridge Technologies (PBTS) +31%.Auddia (AUUD) +23%.Amesite (AMST) +22%.Global Internet of Peopl...
SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. In addition, Aligos intends to grant the underwriters a 30-day option to purchas...
- First clinical data presented for ALG-010133, which is in development for S-antigen reduction in chronic hepatitis B (CHB) patients -Presentations include nonclinical data from 3 other CHB programs SOUTH SAN FRANCISCO, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Aligos Therape...
-Five scientific posters to be presented at upcoming EASL ILC meeting - All 4 Aligos CHB development candidates continue to advance – STOPS™ molecule and CAM drug candidates are currently being evaluated in CHB subjects - ASO and siRNA drug candidates are on track to e...
News, Short Squeeze, Breakout and More Instantly...
Aligos Therapeutics Inc. Company Name:
ALGS Stock Symbol:
NASDAQ Market:
Aligos Therapeutics Inc. Website:
Key Opinion Leader (KOL) event with Dr. Mark Sulkowski to discuss his perspectives on the chronic suppression regulatory pathway and future development plans following positive feedback from the FDA to move forward with chronic HBV DNA suppression as the primary efficacy endpoint Schedu...
2024-07-09 10:10:00 ET July 9, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Tech, Biotech, Cleantech and Mining Sectors. The newest tech company is involved in AI and Blo...
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive...